Paradigm Biopharmaceuticals completes Zilosul dosing under FDA’s Expanded Access Program
Paradigm Biopharmaceuticals targets 2019-20 milestones for OA-MPS-BMEL pipeline
G Medical Innovations eyes significant revenue growth in the UK and US
Only registered members can use this feature.
Copyright © Proactive Investors 2019.
All Rights Reserved - Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.